Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NVAX |
---|---|---|
09:32 ET | 145782 | 11.72 |
09:34 ET | 81526 | 11.81 |
09:36 ET | 24144 | 11.86 |
09:38 ET | 86233 | 11.96 |
09:39 ET | 26068 | 12.04 |
09:41 ET | 25539 | 11.9399 |
09:43 ET | 23436 | 11.92 |
09:45 ET | 17246 | 11.85 |
09:48 ET | 16296 | 11.91 |
09:50 ET | 24228 | 11.92 |
09:52 ET | 24413 | 11.89 |
09:54 ET | 28598 | 11.95 |
09:56 ET | 11564 | 11.89 |
09:57 ET | 9166 | 11.88 |
09:59 ET | 23919 | 11.93 |
10:01 ET | 27676 | 11.905 |
10:03 ET | 15527 | 11.895 |
10:06 ET | 37183 | 11.87 |
10:08 ET | 17463 | 11.91 |
10:10 ET | 11951 | 11.8383 |
10:12 ET | 38602 | 11.865 |
10:14 ET | 9042 | 11.8201 |
10:15 ET | 17943 | 11.79 |
10:17 ET | 16592 | 11.785 |
10:19 ET | 27739 | 11.745 |
10:21 ET | 18933 | 11.82 |
10:24 ET | 15270 | 11.8429 |
10:26 ET | 32601 | 11.885 |
10:28 ET | 10885 | 11.87 |
10:30 ET | 28127 | 11.855 |
10:32 ET | 11523 | 11.84 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Novavax Inc | 1.7B | -3.7x | --- |
PTC Therapeutics Inc | 2.4B | -4.1x | --- |
ACADIA Pharmaceuticals Inc | 2.7B | -1,248.5x | --- |
Azenta Inc | 2.8B | -19.2x | --- |
P3 Health Partners Inc | 178.9M | -0.9x | --- |
Catalyst Pharmaceuticals Inc | 1.8B | 28.7x | --- |
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.7B |
---|---|
Revenue (TTM) | $996.6M |
Shares Outstanding | 140.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.97 |
EPS | $-3.18 |
Book Value | $-5.14 |
P/E Ratio | -3.7x |
Price/Sales (TTM) | 1.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -39.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.